Nirmatrelvir/Ritonavir

Kathryn Dzintars, Pharm.D., BCPS
Nirmatrelvir/Ritonavir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) for the emergency use of Paxlovid (nirmatrelvir/ritonavir) for the treatment of mild-to-moderate COVID-19 disease in adults and pediatric (≥ 12 years of age) with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk factors for severe disease include diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, and patients > 60 years of age.

Paxlovid is NOT authorized for:

  • Initiation of treatment for patients requiring hospitalization
  • Pre-exposure or post-exposure prophylaxis for prevention of COVID-19
  • Use longer than 5 consecutive days

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) for the emergency use of Paxlovid (nirmatrelvir/ritonavir) for the treatment of mild-to-moderate COVID-19 disease in adults and pediatric (≥ 12 years of age) with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk factors for severe disease include diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, and patients > 60 years of age.

Paxlovid is NOT authorized for:

  • Initiation of treatment for patients requiring hospitalization
  • Pre-exposure or post-exposure prophylaxis for prevention of COVID-19
  • Use longer than 5 consecutive days

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: January 4, 2022